NASDAQ : NDRA
ENDRA Life Sciences Inc. — Financial statements
Healthcare · Diagnostics & Research · United States
Last price 4.75 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.12M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 4.70M | 3.91M | 7.63M | 5.52M | 6.60M | 6.02M |
| Research & Development | 1.95M | 1.85M | 3.19M | 5.00M | 6.55M | 5.48M |
| Operating Expenses | 6.65M | 5.76M | 10.82M | 10.52M | 13.16M | 11.50M |
| Operating Income | -6.65M | -5.76M | -10.82M | -10.52M | -13.16M | -11.50M |
| Other Non Operating Income (Expenses) | 707.20K | -1.27M | -3.77M | 460.49K | -21.53K | -41.55K |
| EBT Excluding Unusual Items | -5.94M | -7.03M | -14.58M | -10.06M | -13.18M | -11.54M |
| Other Unusual Items | 25.88K | 5.12K | 3.08M | 308.60K | ||
| Pretax Income | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
| Net Income | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
| Preferred Dividends & Other Adjustments | 121.07K | |||||
| Net Income to Common | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.35M |
| Shares Outstanding (Basic) | 1.10M | 787.02K | 202.11K | |||
| Shares Outstanding (Diluted) | 1.10M | 787.02K | 202.11K | |||
| EPS (Basic) | -5.38 | -8.93 | -56.94 | |||
| EPS (Diluted) | -5.38 | -8.93 | -56.94 | |||
| Free Cash Flow | -4.84M | -5.20M | -7.42M | -9.58M | -12.97M | -11.17M |
| Free Cash Flow Per Share | -4.40 | -6.61 | -36.70 | |||
| EBITDA | -6.61M | -5.72M | -10.77M | -10.40M | -13.06M | -11.38M |
| D&A For EBITDA | 38.55K | 44.05K | 46.49K | 123.73K | 96.66K | 116.24K |
| EBIT | -6.65M | -5.76M | -10.82M | -10.52M | -13.16M | -11.50M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 1.74M | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M |
| Cash & Short-Term Investments | 1.74M | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M |
| Inventory | 1.28M | |||||
| Prepaid Expenses | 47.06K | 205.60K | 204.19K | 198.91K | 490.30K | 1.35M |
| Total Current Assets | 5.59M | 967.97K | 3.43M | 3.03M | 5.38M | 12.09M |
| Property, Plant & Equipment | 444.25K | 504.46K | 647.29K | 465.87K | 741.47K | 774.54K |
| Other Long-Term Assets | 1.91M | 2.38M | 371.40K | 3.26M | 3.15M | 5.99K |
| Total Assets | 7.94M | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M |
| Accounts Payable | 464.98K | 382.97K | 269.68K | 360.40K | 613.96K | 791.05K |
| Accrued Expenses | 182.96K | 238.61K | 238.61K | 191.56K | 750.13K | 503.25K |
| Short-Term Debt | 148.79K | 158.93K | 117.13K | |||
| Current Portion of Long-Term Debt | 28.48K | 28.48K | ||||
| Current Portion of Leases | 138.64K | 129.38K | 96.94K | 173.86K | 152.23K | 132.33K |
| Total Current Liabilities | 786.58K | 750.96K | 605.23K | 903.10K | 1.70M | 1.54M |
| Long-Term Debt | 28.48K | |||||
| Long-Term Leases | 290.63K | 362.97K | 487.48K | 192.06K | 365.92K | 518.15K |
| Other Long-Term Liabilities | 555.31K | 479.75K | 799.28K | |||
| Total Liabilities | 1.63M | 1.59M | 1.89M | 1.10M | 2.07M | 2.09M |
| Common Stock | 148.00 | 116.00 | 53.00 | 1.00 | 317.00 | 212.00 |
| Additional Paid-In Capital | 118.00M | 112.73M | 106.00M | 97.58M | 89.07M | 79.46M |
| Retained Earnings | -111.62M | -110.47M | -103.44M | -91.93M | -81.87M | -68.69M |
| Comprehensive Income & Other | -72.98K | 5.23K | 6.07K | 13.86K | ||
| Total Common Equity | 6.31M | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
| Shareholders' Equity | 6.31M | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
| Total Liabilities & Equity | 7.94M | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M |
| Total Debt | 429.27K | 492.35K | 584.42K | 543.20K | 705.56K | 796.09K |
| Net Cash (Debt) | 1.31M | 270.01K | 2.65M | 2.29M | 4.18M | 8.67M |
| Net Cash Per Share | 1.19 | 0.34 | 13.09 | |||
| Filing Date Shares Outstanding | 1.50M | 1.24M | 562.21K | |||
| Total Common Shares Outstanding | 1.50M | 1.18M | 536.91K | |||
| Working Capital | 4.80M | 217.01K | 2.83M | 2.13M | 3.68M | 10.55M |
| Book Value Per Share | 4.21 | 1.92 | 4.77 | |||
| Tangible Book Value | 6.31M | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
| Tangible Book Value Per Share | 4.21 | 1.92 | 4.77 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
| Depreciation & Amortization | 157.80K | 157.29K | 206.17K | 275.45K | 234.26K | 224.41K |
| Asset Writedown & Restructuring Costs | 8.81K | 24.87K | 1.39K | 9.87K | ||
| Stock-Based Compensation | 1.20M | 329.41K | 571.92K | 996.43K | 1.20M | 1.44M |
| Other Operating Activities | -699.00K | 1.34M | 3.19M | 138.04K | -308.60K | |
| Change in Inventory | 235.73K | -116.19K | -1.36M | -694.96K | ||
| Change in Accounts Payable | 199.51K | 113.29K | -198.87K | -822.26K | 111.58K | 491.10K |
| Change in Other Net Operating Assets | 234.45K | -90.67K | 97.22K | 15.13K | 222.80K | -1.06M |
| Operating Cash Flow | -4.82M | -5.18M | -7.40M | -9.55M | -12.77M | -11.12M |
| Capital Expenditures | -18.67K | -17.28K | -16.00K | -33.88K | -202.58K | -45.00K |
| Sale of Property, Plant & Equipment | 3.20K | 9.16K | ||||
| Sale (Purchase) of Intangibles | -314.23K | -3.00M | ||||
| Investing Cash Flow | -332.89K | -3.02M | -12.80K | -24.72K | -202.58K | -45.00K |
| Long-Term Debt Repaid | -28.48K | |||||
| Total Debt Repaid | -28.48K | |||||
| Net Debt Issued (Repaid) | -28.48K | |||||
| Issuance of Common Stock | 8.89M | 5.73M | 7.84M | 6.48M | 8.40M | 13.40M |
| Other Financing Activities | 1.03M | |||||
| Financing Cash Flow | 8.89M | 5.73M | 7.81M | 7.52M | 8.40M | 13.40M |
| Miscellaneous Cash Flow Adjustments | -1.00 | |||||
| Net Cash Flow | 3.73M | -2.47M | 395.57K | -2.06M | -4.57M | 2.23M |
| Free Cash Flow | -4.84M | -5.20M | -7.42M | -9.58M | -12.97M | -11.17M |
| Free Cash Flow Per Share | -4.40 | -6.61 | -36.70 | |||
| Levered Free Cash Flow | -6.73M | -6.02M | -6.05M | -5.86M | -4.78M | -6.75M |
| Unlevered Free Cash Flow | -6.73M | -6.02M | -6.05M | -5.86M | -4.78M | -6.75M |
| Cash Interest Paid | 55.85K | 55.85K | 31.91K | 44.98K | 59.11K | 57.66K |
| Change in Working Capital | 433.96K | 22.62K | 134.08K | -923.32K | -1.03M | -1.26M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 7.12M | 5.28M | 3.36M | 17.92M | 12.85M | 29.15M |
| Enterprise Value | 5.81M | 5.02M | -938.80K | 15.24M | 5.65M | 18.27M |
| Last Close Price | 4.75 | 4.53 | 6.26 | 3,710.00 | 7,122.51 | 24,213.02 |
| PB Ratio | 1.13 | 2.34 | 1.31 | 3.17 | 1.78 | 2.70 |
| P/TBV Ratio | 1.13 | 2.34 | 1.31 | 3.17 | 1.78 | 2.70 |
| Debt / Equity Ratio | 0.07 | 0.22 | 0.23 | 0.10 | 0.10 | 0.07 |
| Net Debt / Equity Ratio | -0.21 | -0.12 | -1.03 | -0.41 | -0.58 | -0.80 |
| Net Debt / EBITDA Ratio | 0.20 | 0.05 | 0.25 | 0.22 | 0.32 | 0.76 |
| Net Debt / FCF Ratio | 0.27 | 0.05 | 0.36 | 0.24 | 0.32 | 0.78 |
| Quick Ratio | 2.21 | 1.01 | 5.34 | 3.14 | 2.87 | 6.13 |
| Current Ratio | 7.10 | 1.29 | 5.67 | 3.36 | 3.16 | 7.83 |
| Return on Equity (ROE) | -152.04% | -291.56% | -280.02% | -156.42% | -146.53% | -125.11% |
| Return on Assets (ROA) | -77.32% | -86.73% | -120.66% | -82.05% | -74.26% | -66.42% |
| Return on Capital Employed (ROCE) | -92.90% | -185.70% | -281.20% | -179.80% | -173.80% | -101.50% |
| Earnings Yield | -113.30% | -133.00% | -342.39% | -56.13% | -102.57% | -38.53% |
| FCF Yield | -67.96% | -98.41% | -220.66% | -53.47% | -100.96% | -38.31% |
| Buyback Yield / Dilution | -113.32% | -289.41% |